The US Food and Drug Administration has recently approved MindMotion GO, a mobile rehabilitation therapy system designed to motivate and engage patients in daily rehabilitation.
The system is designed for use by patients with light-and medium-severity neurologic impairments to augment their motivation to increase their rehabilitation dose and intensity. It also provides continued therapy later in the recovery phase, primarily on an outpatient basis, according to a media release from its developer, MindMaze, with offices in Lausanne, Switzerland, and San Francisco.
MindMotion GO is an outpatient addition to the company’s MindMotion PRO, which received FDA approval in May 2017. MindMotion PRO is designed for patients with severe impairments and for early hospital care, allowing for therapeutic activities as early as 4 days after a neurologic incident.
“Now that both MindMotion products have FDA clearance, MindMaze delivers a full spectrum of neuro-care solutions for both inpatient and outpatient recovery for patients in the United States,” says Tej Tadi, CEO and founder of MindMaze, in the release.
MindMotion GO includes a variety of gamified activities covering motor and task functions in a three-dimensional virtual environment. These games feature real-time audio and visual feedback to help therapists assess a patient’s progress and to tailor the therapy accordingly. Patients can also monitor their progress as they participate in the activities.
[Source: Medscape Neurology News]